Today: 1 May 2026
Lockheed Martin stock steadies near highs after Jefferies lifts target — here’s what Wall Street watches next
13 January 2026
1 min read

Lockheed Martin stock steadies near highs after Jefferies lifts target — here’s what Wall Street watches next

New York, Jan 12, 2026, 19:24 EST — After-hours

  • Lockheed Martin shares closed Monday’s regular session up 1.5%, at $551.24.
  • Jefferies raised its price target to $540 from $500 but maintained a “Hold” rating.
  • Lockheed’s next key moment arrives Jan. 29 with its earnings report, when guidance and commentary will come under scrutiny.

Lockheed Martin Corp shares gained 1.5% Monday, closing at $551.24. The defense giant remains close to a new 52-week peak following a series of policy-fueled moves in the sector.

Why it matters now: traders face a dual challenge—gauging a White House capable of shifting the sector on a single headline, while also sizing up a company approaching earnings amid investors already favoring defense. Some are quick to adapt, others just buy the dips.

The sector’s vulnerability was clear last week: Lockheed shares dropped roughly 7% late Wednesday after U.S. President Donald Trump announced he would bar dividends and buybacks at defense companies. They then jumped about 8% in after-hours trading when he proposed boosting the defense budget by 50% to $1.5 trillion.

“Investors don’t necessarily view the string of market interventions as seriously undermining the rule of law and property rights,” William Henagan, a research fellow at the Council on Foreign Relations, told Reuters. Reuters

Jefferies lifted its price target on Lockheed to $540 from $500 on Tuesday but maintained a “Hold” rating. The move suggests the firm sees some upside potential, though not enough to get bullish right now. A price target reflects where analysts expect a stock to trade over the next year. Investing.com

Jefferies highlighted potential catalysts in its note, including new contract wins and accelerated programs like PAC-3 missiles. The firm expects margins to “stabilize” around 11% by 2026. It also mentioned possible portfolio shifts that could unlock value.

That said, the broker cautioned that Lockheed’s 2026 revenue and earnings-per-share guidance might fall slightly short, even if fourth-quarter revenue hits the expected mark. Earnings per share, which is profit divided by shares outstanding, remains a key measure of performance.

Lockheed’s jump Monday coincided with rallies in fellow defense giants Northrop Grumman and General Dynamics, as money flowed into the sector even though the wider market barely budged.

The setup looks complicated. Should Washington impose stricter payout limits or procurement schedules delay, the sector could see a rapid rerating. Stocks trading near their peaks offer little room for a cautious stance.

Traders will be eyeing any new cues from Washington on defense budgets and disbursements in the next session, along with the steady stream of Pentagon contracts that often sway views on the backlog.

Lockheed is set to release its Q4 and full-year results on Jan. 29, followed by a conference call.

Stock Market Today

  • Eli Lilly (LLY) Valuation Seen as 21% Undervalued Amid Robust Growth Prospects
    May 1, 2026, 12:56 PM EDT. Eli Lilly's (LLY) share price surged 9.8% in one day to $934.60, marking strong momentum after a multi-year rally with a market cap near $762 billion and $65.2 billion annual revenue. The stock delivered an 18.56% total return over the past year and quadrupled over five years. Analysts estimate a fair value around $1,189, implying about 21% undervaluation based on forecasted 20-25% annual revenue growth driven by limited competition and capacity expansion. However, the firm's 40.5 times price-to-earnings (P/E) ratio far exceeds the U.S. pharma average of 16.1, reflecting lofty expectations and risks including production delays and product side effects. Investors face a balance between sustaining premium pricing and navigating emerging market challenges.

Latest article

Roku Stock Rises After Bigger 2026 Revenue Bet, With One Cost Risk in View

Roku Stock Rises After Bigger 2026 Revenue Bet, With One Cost Risk in View

1 May 2026
Roku raised its 2026 platform revenue forecast to nearly 21% growth, or about $5.0 billion, after first-quarter advertising and subscription sales beat expectations. Shares climbed 4.2% Friday, with the stock up 10% in after-hours trading. Platform revenue rose 28% to $1.13 billion, while devices revenue fell 16%. Rising memory costs remain the main risk for the second half.
Zeta Global (ZETA) Stock Rises as AI Push Fuels 50% Revenue Growth, Bigger 2026 Target

Zeta Global (ZETA) Stock Rises as AI Push Fuels 50% Revenue Growth, Bigger 2026 Target

1 May 2026
Zeta Global shares rose after the company raised its 2026 revenue outlook and reported a 50% jump in first-quarter sales to $396.3 million, beating consensus. The company cited strong adoption of its Athena AI agent and growth in “super-scaled” customers. Adjusted EBITDA climbed to $66.1 million from $46.7 million. The stock traded at $19.17, up 75 cents in late-morning New York trading.
Rivian Stock Slides as Smaller Federal Loan Puts Its R2 SUV Bet Under the Microscope

Rivian Stock Slides as Smaller Federal Loan Puts Its R2 SUV Bet Under the Microscope

1 May 2026
Rivian shares fell 5.7% to $15.47 after the company said its federal loan for a Georgia factory would be cut to $4.5 billion. First-quarter revenue rose 11% to $1.38 billion, with a net loss of $416 million. Rivian kept its 2026 delivery forecast and reported 10,236 vehicles produced in Q1. Volkswagen invested $1 billion after software milestones; Uber-linked SMB Holding agreed to invest up to $1.25 billion.
GE Vernova stock pops after $1,087 price-target hike — and Wall Street’s already eyeing Jan. 28
Previous Story

GE Vernova stock pops after $1,087 price-target hike — and Wall Street’s already eyeing Jan. 28

AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land
Next Story

AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

Go toTop